Abstract 3350
Background
Clinical pathways in oncology have become increasingly complex, involving several different healthcare professionals inside and outside the hospital setting who need particular coordination to provide appropriate care for patients. Very few QI exist to evaluate the oncological clinical pathway in its entirety, particularly regarding the various stages between patient admissions and discharges and the liaisons with non-hospital healthcare professionals (e.g. GPs, pharmacists). Our objective is to select a number of QI describing the oncological clinical pathway with an expert panel.
Methods
A systematic review of available QI describing the oncological clinical pathways in the literature was conducted. The list of selected QI was presented to an expert panel (oncologists, pharmacists and SRNs) of various hospitals in France. The selection involved a two-step process: a preliminary selection was conducted based on the title and rationale of the QI by consensus (nominal group), assigning a value to each QI reviewed on the basis of its appropriateness and its feasibility (1st working group). The pre-selected QI were then described in detail and presented to the expert panel (2nd working group) in order to validate the selection.
Results
5731 QI were identified in the literature review and 131 included. 17 indicators were pre-selected by the experts (1st working group). After presentation of the 17 detailed descriptors, the QIs were clustered or eliminated. Ultimately, 10 QI were selected (Table): outcome (2), process (3) and structure (5).Table: 1658P
QI | Description | Type |
---|---|---|
1 | Symptoms and disease progression | Structure |
2 | Assessment of tolerance to treatment | Process |
3 | Management of patients receiving oral therapy | Structure |
4 | Quality of the liaison document | Process |
5 | Composite score for supportive care | Structure |
6 | Patient therapeutic education | Structure |
7 | Medication reconciliation | Process |
8 | Unscheduled admissions | Outcome |
9 | Declaration and follow-up upon serious adverse events in clinical pathway | Structure |
10 | Patient’s experience (PREMS) | Outcome |
Conclusions
This approach will be developed further by presenting the IQs to patient associations and primary care physicians in order to gather their feedback, refine, adapt and ultimately create a representative set of indicators.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Novartis Oncology France.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract